High unmet need and strong scientific rationale
A clear exposure-response or dose-timing relationship
Meaningful patient heterogeneity
Measurable efficacy and safety signals
An accelerated or more efficient development path
Commercial differentiation potential
An asset-specific collaboration only if the evidence supports it — testable without disrupting your current plans. Leverage is highest before pivotal design and label strategy are locked.
A first conversation about fit — no confidential data required.
A confidential, staged asset evaluation against the strong-fit criteria.
An asset-specific collaboration, only if the evidence supports it.
connecting@translationalcures.com
Contact us